MicroRNAs as biomarkers for hepatocellular carcinoma: A diagnostic meta-analysis

Clinical Laboratory

Volumn 59, Issue 9-10, 2013, Pages 1113-1120

  Hu, Qiong Ying ^a   Jiang, Hong ^a   Su, Jun ^a   Jia, Yong Qian ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Hepatocellular carcinoma; Meta analysis; MicroRNAs

Indexed keywords

BIOLOGICAL MARKER; MICRORNA;

ARTICLE; CANCER SCREENING; DATA BASE; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; FULL TEXT DATABASE; HUMAN; LITERATURE; LIVER CELL CARCINOMA; MAXIMUM LIKELIHOOD METHOD; META ANALYSIS; SENSITIVITY AND SPECIFICITY; TASK PERFORMANCE;

AGED; BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; HUMANS; LIKELIHOOD FUNCTIONS; LIVER NEOPLASMS; MICRORNAS; MIDDLE AGED; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 84886422148     PISSN: 14336510     EISSN: None     Source Type: Journal    
DOI: 10.7754/Clin.Lab.2012.121102     Document Type: Article

References (36)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics. CA Cancer J Clin 2012;62:10-29.
2. Hu Q, Huang Y, Wang Z, et al. Application of Surface-Enhanced Laser Desorption/Ionization Time-of-Flight Mass Spectrometry Coupled With an Artificial Neural Network Model for the Diagnosis of Hepatocellular Carcinoma. Hepatogastroenterology 2012;59:1902-6.
3. Riener MO, Stenner F, Liewen H, et al. Alpha-fetoprotein and serum golgi phosphoprotein 2 are equally discriminative in detecting early hepatocellular carcinomas. Hepatology 2009;50:326.
4. Liu AM, Yao TJ, Wang W, et al. Circulating miR-15b and miR-130b in serum as potential markers for detecting hepatocellular carcinoma: a retrospective cohort study. BMJ Open 2012;2:-e000825.
5. Colli A, Fraquelli M, Casazza G, et al. Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma: a systematic review. Am J Gastroenterol 2006;101:513-23. (Pubitemid 43340927)
6. Marrero JA. Screening tests for hepatocellular carcinoma. Clin Liver Dis 2005;9:235-51.
7. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116:281-97.
8. Amaral PP, Mattick JS. Noncoding RNA in development. Mamm Genome 2008;19:454-92.
9. Yamashita S, Yamamoto H, Mimori K, et al. MicroRNA-372 is associated with poor prognosis in colorectal cancer. Oncology 2012;82:205-12.
10. Weiland M, Gao XH, Zhou L, et al. Small RNAs have a large impact: Circulating microRNAs as biomarkers for human diseases. RNA Biol 2012;9:850-9 [Epub ahead of print].
11. Tjensvoll K, Svendsen KN, Reuben JM, et al. miRNA expression profiling for identification of potential breast cancer biomarkers. Biomarkers 2012:17;463-70 [Epub ahead of print].
12. Papaconstantinou I, Karakatsanis A, Gazouli M, et al. The role of microRNAs in liver cancer. Eur J Gastroenterol Hepatol 2012;24:223-8.
13. Whiting P, Rutjes AW, Reitsma JB, et al. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol 2003;3:25.
14. Whiting P, Harbord R, Kleijnen J. No role for quality scores in systematic reviews of diagnostic accuracy studies. BMC Med Res Methodol 2005;5:19.
15. Qu KZ, Zhang K, Li H, et al. Circulating microRNAs as biomarkers for hepatocellular carcinoma. J Clin Gastroenterol 2011;45:55-60.
16. Gui J, Tian Y, Wen X, et al. Serum microRNA characterization identifies miR-885-5p as a potential marker for detecting liver pathologies. Clin Sci (Lond) 2010;120:183-93.
17. Tomimaru Y, Eguchi H, Nagano H, et al. Circulating microRNA-21 as a novel biomarker for hepatocellular carcinoma. J Hepatol 2012;56:167-75.
18. Harbord RM, Deeks JJ, Egger M, et al. A unification of models for meta-analysis of diagnostic accuracy studies. Biostatistics 2007;8:239-51. (Pubitemid 46569586)
19. Zhou J, Yu L, Gao X, et al. Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma. J Clin Oncol 2011;29:4781-8.
20. Li L, Guo Z, Wang J, et al. Serum miR-18a: A Potential Marker for Hepatitis B Virus-Related Hepatocellular Carcinoma Screening. Dig Dis Sci 2012;57:2910-6.
21. Puerta-Gil P, Garcia-Baquero R, Jia AY, et al. miR-143, miR-222, and miR-452 are useful as tumor stratification and noninvasive diagnostic biomarkers for bladder cancer. Am J Pathol 2012;180:1808-15.
22. Piepoli A, Tavano F, Copetti M, et al. Mirna expression profiles identify drivers in colorectal and pancreatic cancers. PLoS One 2012;7:e33663.
23. Nair VS, Maeda LS, Ioannidis JP. Clinical outcome prediction by microRNAs in human cancer: a systematic review. J Natl Cancer Inst 2012;104:528-40.
24. Fiorucci G, Chiantore MV, Mangino G, et al. Cancer regulator microRNA: potential relevance in diagnosis, prognosis and treatment of cancer. Curr Med Chem 2012;19:461-74.
25. Yu DC, Li QG, Ding XW, et al. Circulating MicroRNAs: Potential Biomarkers for Cancer. Int J Mol Sci 2011;12:2055-63.
26. Lendvai G, Kiss A, Kovalszky I, et al. [MicroRNAs in hepatocarcinogenesis], Orv Hetil 2012;153:978-89.
27. Banaudha KK, Verma M. The role of microRNAs in the management of liver cancer. Methods Mol Biol 2012;863:241-51.
28. Yoon SO, Chun SM, Han EH, et al. Deregulated expression of microRNA-221 with the potential for prognostic biomarkers in surgically resected hepatocellular carcinoma. Hum Pathol 2011;42:1391-400.
29. Li T, Li RS, Li YH, et al. MiR-21 as an independent biochemical recurrence predictor and potential therapeutic target for prostate cancer. J Urol 2012;187:1466-72.
30. Zhang HL, Yang LF, Zhu Y, et al. Serum miRNA-21: elevated levels in patients with metastatic hormone-refractory prostate cancer and potential predictive factor for the efficacy of docetaxel-based chemotherapy. Prostate 2011;71:326-31.
31. Zhao R, Wu J, Jia W, et al. Plasma miR-221 as a predictive biomarker for chemoresistance in breast cancer patients who previously received neoadjuvant chemotherapy. Onkologie 2011;34:-675-80.
32. Li J, Wang Y, Yu W, et al. Expression of serum miR-221 in human hepatocellular carcinoma and its prognostic significance. Biochem Biophys Res Commun 2011;406:70-3.
33. Bihrer V, Waidmann O, Friedrich-Rust M, et al. Serum microRNA-21 as marker for necroinflammation in hepatitis C patients with and without hepatocellular carcinoma. PLoS One 2011;6:e26971.
34. Li LM, Hu ZB, Zhou ZX, et al. Serum microRNA profiles serve as novel biomarkers for HBV infection and diagnosis of HBV-positive hepatocarcinoma. [Erratum appears in Cancer Res 2011 Mar 1;71(5):2022], Cancer Res 2010;70:9798-807.
35. Leeflang MM, Debets-Ossenkopp YJ, Visser CE, et al. Galactomannan detection for invasive aspergillosis in immunocompromized patients. Cochrane Database Syst Rev 2008;8:CD007394.
36. Qi P, Cheng SQ, Wang H, et al. Serum microRNAs as biomarkers for hepatocellular carcinoma in Chinese patients with chronic hepatitis B virus infection. PLoS One 2011;6:e28486.